Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA, BSE: 524715), one of the world’s leading pharmaceutical companies, has announced the appointment of Richard Ascroft as the new Chief Executive Officer (CEO) for North America, effective June 16, 2025. With over 30 years of experience in the pharmaceutical industry, Richard brings a strong track record of leadership, innovation, and strategic execution across key global markets.
In his new role, Richard will oversee Sun Pharma’s operations across the U.S. and Canada, driving the growth of its innovative therapies, generic medicines, and over-the-counter (OTC) products. His extensive background spans commercial strategy, market access, clinical development, and corporate affairs, positioning him to lead the company through its next phase of expansion.
Richard's appointment comes at a pivotal time as Sun Pharma prepares for upcoming product launches, including novel treatments for alopecia areata and squamous cell carcinoma. His expertise is expected to play a vital role in steering the North America business towards sustained growth and greater market presence.
“It is an honor to join Sun Pharma as CEO for North America,” said Richard Ascroft. “This is a remarkable opportunity to lead a talented team and support the delivery of both generic and innovative medicines that improve patients’ lives. As Sun Pharma continues to grow, the North American market remains a key driver for launching breakthrough therapies and expanding patient access to high-quality treatments.”
Richard succeeds Abhay Gandhi, who made significant contributions to the development of the company’s North American footprint. As CEO, Richard will report directly to Aalok Shanghvi, Sun Pharma’s Whole-time Director and Chief Operating Officer.
Commenting on the appointment, Aalok Shanghvi said, “Richard brings a wealth of experience and a deep understanding of the U.S. healthcare landscape. His strategic vision and leadership will be critical in helping us deliver on our mission to improve health outcomes and enhance quality of life for patients across North America.”
Before joining Sun Pharma, Richard served as Senior Vice President and Business Unit Head of U.S. Plasma-Derived Therapies at Takeda Pharmaceuticals, where he was a member of both the U.S. and global executive leadership teams.